Drugs / HER-2/neu peptide vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00003002 | Apr 1996 → Jan 2004 | breast cancer, lung cancer, ovarian cancer | University of Washington | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER-2/neu peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003002 ↗ |
| Modality | Vaccine | “Patients receive one of three HER-2/neu peptide vaccine formulations that also contain sargramostim (GM-CSF) as the vaccine adjuvant.” NCT00003002 ↗ |